In vitro study reveals synergy between PARP and PRMT5 inhibitors in breast cancer cells, suggesting new therapeutic options for patients regardless of BRCA1/2 or MTAP status.
Key Points
Synergy between PARP inhibitors and PRMT5 inhibitors was found in multiple breast cancer cell lines.
All tested cell lines showed sensitivity to combined therapy regardless of BRCA1/2 or MTAP status.
Drug interactions were analyzed using the Loewe method, revealing consistent efficacy across different backgrounds.
These findings support further exploration of combining PRMT5 and PARP inhibitors in breast cancer treatment beyond genetic mutation contexts.